Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itacitinib plus corticosteroids for steroid-naive acute GVHD in Japanese patients
jRCT2080224148Phase 1Completed
- Sponsor
- Incyte
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of itacitinib in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Incyte. Primary endpoints: Safety and tolerability of itacitinib in combination with corticosteroids and Pharmacokinetics of itacitinib. Started Nov 2018; status: completed.
02
Drugs
itacitinib
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on jRCT2080224148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224148.